0001209191-18-017693.txt : 20180307
0001209191-18-017693.hdr.sgml : 20180307
20180307161340
ACCESSION NUMBER: 0001209191-18-017693
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180305
FILED AS OF DATE: 20180307
DATE AS OF CHANGE: 20180307
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Bozigian Haig P.
CENTRAL INDEX KEY: 0001423837
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-22705
FILM NUMBER: 18673519
MAIL ADDRESS:
STREET 1: 12790 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC
CENTRAL INDEX KEY: 0000914475
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 330525145
STATE OF INCORPORATION: CA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: (858) 617-7600
MAIL ADDRESS:
STREET 1: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-03-05
0
0000914475
NEUROCRINE BIOSCIENCES INC
NBIX
0001423837
Bozigian Haig P.
12780 EL CAMINO REAL
SAN DIEGO
CA
92130
0
1
0
0
Chief Development Officer
Common Stock
2018-03-05
4
M
0
61474
5.76
A
197471
D
Common Stock
2018-03-05
4
S
0
61474
90.00
D
135997
D
Common Stock
2018-03-05
4
M
0
14399
43.24
A
150396
D
Common Stock
2018-03-05
4
S
0
14399
90.00
D
135997
D
Non-Qualified Stock Option
5.76
2018-03-05
4
M
0
61474
5.76
A
2021-08-25
Common Stock
61474
18243
D
Non-Qualified Stock Option
43.24
2018-03-05
4
M
0
14399
43.24
A
2027-02-06
Common Stock
14399
59460
D
The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
The option was granted August 25, 2011 and vested in 36 equal monthly installments beginning September 25, 2011.
Option granted February 06, 2017 and vested monthly over four years.
/s/ Darin Lippoldt, Attorney-in-Fact
2018-03-07